Risk-Based Monitoring Flashcards
7 cards from real CCDM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Risk-Based Monitoring flashcards as text
What is the primary purpose of a Risk Assessment and Categorization Tool (RACT) in clinical trial planning?
Answer: To systematically identify, score, and prioritize risks by their likelihood and impact to inform the monitoring strategy
A RACT provides a structured framework for identifying potential risks, scoring them on likelihood and impact, and using those scores to prioritize monitoring resources and mitigation efforts.
In a risk-based monitoring program, what distinguishes a 'critical process' from a 'critical data element'?
Answer: A critical process is a workflow whose failure could impact subject rights or data integrity; a critical data element is a specific data point whose accuracy is essential to study conclusions
ICH E6(R2) distinguishes between critical processes (activities like informed consent or randomization that protect subjects and study integrity) and critical data (specific variables central to safety or efficacy determination).
During centralized review, a site shows a consistently low rate of protocol deviations compared to all other sites. How should this be interpreted in a risk-based monitoring framework?
Answer: An unusually low deviation rate may itself be a signal warranting investigation for potential underreporting
An implausibly low rate of protocol deviations compared to other sites can indicate underreporting rather than excellent compliance, and is a recognized signal in centralized monitoring that warrants investigation.
Which of the following represents a valid KRI for detecting data integrity issues at a clinical site?
Answer: Percentage of electronic data capture queries outstanding beyond 30 days
The percentage of unresolved EDC queries beyond a defined timeframe is a direct, measurable indicator of a site's data quality and responsiveness, making it a standard KRI in risk-based monitoring plans.
How does the TransCelerate Biopharma RBM consortium's approach influence industry practice for risk-based monitoring?
Answer: It provides voluntary industry-consensus guidance, toolkits, and example KRI libraries that sponsors can adapt to their programs
TransCelerate's RBM consortium developed widely adopted voluntary frameworks and example KRI libraries that harmonize RBM practices across the industry without creating mandatory regulatory requirements.
When outsourcing monitoring activities to a CRO in an RBM program, what must the sponsor ensure according to ICH E6(R2)?
Answer: The sponsor retains ultimate oversight responsibility and must confirm the CRO implements the agreed monitoring plan
ICH E6(R2) is explicit that sponsors cannot delegate regulatory responsibility — even when a CRO is used, the sponsor retains ultimate accountability and must maintain oversight of the CRO's monitoring activities.
Which best describes how risk-based monitoring documentation should be maintained throughout a clinical trial?
Answer: Ongoing documentation of signals detected, actions taken, and any protocol-justified modifications to the monitoring plan should be maintained as part of the trial master file
Effective RBM requires a living record — signals, investigations, and adaptive changes to the monitoring strategy must all be documented in the trial master file to demonstrate regulatory compliance and continuous oversight.